NCT04158856View on ClinicalTrials.gov

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2030

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

Pyrotinib

400mg po every day

DRUG

Trastuzumab

Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days

All Listed Sponsors
lead

xuexin he

OTHER